Physician Assistant Program year 2025 Reported 2021–2025 Source: CMS Open Payments, 2026 publication

Srikanth Vangapandu

Physician Assistant Dayton, OH Physician Assistant

NPI 1285009837 CMS profile 10626688

5300 Far Hills Ave, Dayton, OH 45429

Open in the dashboard

General payments

$16,873

1,089 records reported · program years 2021–2025

Research payments

$0

Paid to them · None reported · program years 2021–2025

Ownership & investment interest

$0

None reported

Through program year 2025, Srikanth Vangapandu of Dayton, OH is reported in the CMS Open Payments database as having received $16,873 across 1,089 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 98th percentile of Physician Assistant profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

5 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $5,221 324
2024 General $4,931 328
2023 General $3,584 231
2022 General $1,747 124
2021 General $1,390 82

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Srikanth Vangapandu
  • Physician Assistant median
  • Middle half of Physician Assistant
  • National median

In program year 2025, general payments to Srikanth Vangapandu were reported at $5,221. Among 68,903 Physician Assistant profiles paid that year, the median was $184 and the middle half received between $57 and $620.

Show as a table
Year Srikanth Vangapandu Physician Assistant median Middle half National median
2019 $0 $34 $17–$122 $163
2020 $0 $33 $16–$78 $114
2021 $1,390 $132 $37–$438 $132
2022 $1,747 $155 $48–$522 $149
2023 $3,584 $167 $52–$557 $160
2024 $4,931 $178 $55–$600 $164
2025 $5,221 $184 $57–$620 $169

Breakdown

Who paid General payments · program years 2021–2025
  1. AbbVie, Inc. $2,603 191 payments
  2. Janssen Biotech, Inc. $2,058 128 payments
  3. E.R. Squibb & Sons, L.L.C. $1,219 60 payments
  4. Incyte Corporation $1,066 93 payments
  5. Dermavant Sciences, Inc. $928 82 payments
  6. Journey Medical Corporation $913 40 payments
  7. Regeneron Healthcare Solutions, Inc. $892 45 payments
  8. Pfizer Inc. $812 55 payments
  9. Arcutis Biotherapeutics, Inc. $726 85 payments
  10. UCB, Inc. $703 32 payments
  11. Other $4,952 278 payments

Every payment, record by record

What the payments were for General payments · program years 2021–2025
  1. Food and Beverage $15,615 1,078 payments
  2. Education $757 10 payments
  3. Consulting Fee $500 1 payment
Products named General payments · program years 2021–2025
  1. TREMFYA $1,826 106 payments
  2. RINVOQ $1,296 89 payments
  3. SOTYKTU $1,105 58 payments
  4. OPZELURA $983 92 payments
  5. VTAMA $940 84 payments
  6. SKYRIZI $872 67 payments
  7. CIBINQO $761 52 payments
  8. LITFULO $681 47 payments
  9. Bimzelx $676 31 payments
  10. TALTZ $601 33 payments
  11. Other $9,919 662 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Prescribing to Medicare patients

Part D · data year 2024 · 38 drugs

Part D claims

3,010

Median for Physician Assistant: 241

Drug cost

$617,795

Median for Physician Assistant: $4,110

Branded share of claims

4.7%

Median for Physician Assistant: 19.6%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Cosentyx Sensoready (2 Pens) Secukinumab Brand 26 $207,889
Dupixent Pen Dupilumab Brand 23 $87,162
Humira(Cf) Adalimumab Brand 12 $81,201
Enbrel Sureclick Etanercept Brand 11 $80,465
Otezla Apremilast Brand 16 $77,805
Fluorouracil Generic 246 $23,799
Clobetasol Propionate Generic 386 $15,665
Clindamycin Phosphate Generic 142 $7,881
Tacrolimus Generic 48 $7,627
Triamcinolone Acetonide Generic 389 $2,966

The 10 drugs with the highest cost, of 38 counted.

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 114,276 Part D prescribers listed as Physician Assistant; they describe a distribution and say nothing about conduct.

Billing to Medicare

Part B · data year 2024 · 75 billing codes

Paid by Medicare

$222,800

Of which drugs: $140

Medicare patients

1,367

Average age 74

Services billed

5,617

573 women, 794 men among their patients

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
High blood pressure 68%
Arthritis 44%
Ischemic heart disease 27%
Diabetes 24%
Chronic kidney disease 19%
Atrial fibrillation 16%
Depression 15%
Cancer 13%
Drugs given in the clinic that this provider billed Medicare Part B for
Drug given in the clinic Where Patients Services Paid by Medicare
Injection, triamcinolone acetonide, not otherwise specified, 10 mg J3301 Office 85 256 $139

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Payments and prescribing

First 5 of 27 products · payments 2024

Two separate records. The payments come from Open Payments and the claims from Medicare. They are set side by side because they name the same product; they do not show that a payment affected a prescription.

Products this doctor was paid in connection with in 2024, beside Medicare claims for the same product
Product Paid by Related payments Part D claims Part B services
TREMFYA
$597 — —
VTAMA
$594 — —
SKYRIZI
$443 — —
RINVOQ
$427 — —
SOTYKTU
$388 — —

A dash means Medicare published no figure for this doctor and product — fewer than 11 claims, or the product is not covered under that part — which is not the same as none. Payments are general payments only; one that names several products is split evenly between them, so an amount is payments related to the product, not money paid for it.

See more in the dashboard: 25 with a free account, all 27 with Patron

Records

1,089 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Physician Assistant in Ohio

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record